SCHEMBL5128741

SCHEMBL5128741

Cc1sc2nc(-c3cccnc3)nc(NCc3ccc(F)cc3)c2c1C

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.58
SMN1; SMN2 Q16637 3/20 0.53
PDE5A O76074 7/20 0.53
MEN1 O00255 2/20 0.52
KMT2A Q03164 2/20 0.52
PRKCI P41743 3/20 0.51
GAA P10253 1/20 0.49
RXFP1 Q9HBX9 1/20 0.49
LMNA P02545 2/20 0.48
ALDH1A1 P00352 2/20 0.48
USP2 O75604 1/20 0.48
GBA1 P04062 1/20 0.48
TP53 P04637 1/20 0.48
CYP1A2 P05177 1/20 0.48
CYP3A4 P08684 1/20 0.48
CYP2D6 P10635 1/20 0.48
TSHR P16473 1/20 0.48
PTGS1 P23219 1/20 0.48
TBXAS1 P24557 1/20 0.48
MAPK1 P28482 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7169292 0.94 POLB (0.54) POLBSMN1; SMN2PDE5AMEN1KMT2A
SCHEMBL5123719 0.92 PDE5A (0.58) POLBSMN1; SMN2PDE5AMEN1KMT2A
SCHEMBL5125957 0.90 POLB (0.56) POLBSMN1; SMN2PDE5AMEN1KMT2A
SCHEMBL5117192 0.87 PRKCI (0.67) SMN1; SMN2PRKCIGAARXFP1LMNA
SCHEMBL7171714 0.86 POLB (0.54) POLBSMN1; SMN2PDE5AMEN1KMT2A
SCHEMBL5126022 0.86 CLK4 (0.54) POLBSMN1; SMN2PDE5AMEN1KMT2A
SCHEMBL5816391 0.86 ALDH1A1 (0.61) POLBSMN1; SMN2PDE5AMEN1KMT2A
SCHEMBL5130058 0.84 KMT2A (0.50) POLBSMN1; SMN2PDE5AMEN1KMT2A
SCHEMBL5114966 0.83 SMN1; SMN2 (0.48) POLBSMN1; SMN2PRKCIGAARXFP1
SCHEMBL5116120 0.83 POLB (0.58) POLBSMN1; SMN2PDE5AMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080045529-A1 Use Of Thienopyrimidines MERCK PATENT GMBH (DE) 2008-02-21 US disclosed
US-6432950-B1 ANTICANCER AGENTS; KILLING CANCER CELLS CELL PATHWAYS 2002-08-13 US disclosed
US-6133271-A Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives CELL PATHWAYS, INC. (US) 2000-10-17 US disclosed
US-6110920-A TREATMENT OF CARDIOVASCULAR DISORDERS AND IMPOTENCY MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2000-08-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080045529-A1 Use Of Thienopyrimidines TIE1, DPYD, TK2 POLB 1280/4885SMN1; SMN2 3222/4885PDE5A 2002/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.